Novartis announced FDA traditional approval for Fabhalta (iptacopan) to slow kidney function decline in adults with primary IgAN. The drug demonstrated a 48% reduction in eGFR decline versus placebo over two years in the Phase III APPLAUSE-IgAN study. Fabhalta is the first complement inhibitor approved for this indication and represents a significant advancement in treating this chronic autoimmune kidney disease.

The global autoimmune disease therapeutics market is projected to grow from USD 80.54 billion in 2025 to USD 137.85 billion by 2035, with a CAGR of 5.52%. Growth is driven by rising prevalence of autoimmune diseases, adoption of biologics, JAK inhibitors, monoclonal antibodies, and precision medicine technologies. North America leads with 39.96% market share, while Asia-Pacific shows the fastest growth at 6.28% CAGR.

Novartis and Teva represent different pharmaceutical strategies: Novartis is a stable innovator with high margins and strong cash flow, while Teva is executing a turnaround from generics to biosimilars with improving profitability but higher debt. Despite Novartis's superior financial metrics, the article recommends Teva for long-term investors due to its more attractive valuation ratios and strong drug pipeline expected to drive growth in 2027.

The Vanguard International Dividend Appreciation ETF (VIGI) offers exposure to 343 global stocks from developed markets with a low 0.07% expense ratio, but has delivered underwhelming returns and a modest 2.13% dividend yield. The fund is heavily concentrated in Japan (30.9%) and Canada (23%), and has been significantly outperformed by the S&P 500 over its track record. Analysts suggest more diversified alternatives like the Vanguard International High Dividend Yield ETF (VYMI) may be better for long-term investors.

Vanguard Health Care ETF (VHT) offers broad diversification across 429 healthcare holdings with a low 0.09% expense ratio, while VanEck Pharmaceutical ETF (PPH) provides concentrated exposure to 26 drugmakers with higher returns but greater risk. VHT is more cost-effective and diversified, while PPH has delivered superior 5-year returns and higher dividend yield despite concentration risk and a higher 0.36% expense ratio.

The transthyretin amyloidosis treatment market is projected to grow from USD 8.95 billion in 2025 to USD 35.10 billion by 2035 at a 14.64% CAGR. Growth is driven by increased ATTR-CM diagnosis rates, FDA approvals of gene-silencing therapies like vutrisiran and acoramidis, improved diagnostic imaging, and expanding pipeline therapies. North America dominates with 46% market share, while Asia Pacific is the fastest-growing region.

Novartis has agreed to acquire Brandon Capital's portfolio company Myricx Bio for up to US$1.5 billion, including an upfront payment of US$1.1 billion plus milestone payments. Myricx Bio, a UK-based pre-clinical oncology company, has developed a novel class of N-myristoyltransferase inhibitor (NMTi) payloads for antibody-drug conjugates (ADCs) targeting solid tumors. The acquisition represents a significant exit for Brandon Capital and validates its early-stage investment in the breakthrough cancer therapeutic platform.

Novartis has agreed to acquire Myricx Bio for up to $1.5 billion ($1.1 billion upfront plus milestone payments) to advance next-generation antibody-drug conjugate (ADC) payloads using Myricx's novel N-myristoyltransferase inhibitor (NMTi) platform. The acquisition combines Novartis's oncology expertise with Myricx's differentiated ADC assets targeting solid tumors, addressing unmet needs in overcoming ADC resistance and improving tolerability.

The global photodynamic therapy (PDT) market is expected to grow at a CAGR of 8.3% from 2023 to 2035, driven by minimally invasive treatment demand, expanding applications in oncology and dermatology, and technological innovations. North America is projected to grow at 14% CAGR, while Europe currently holds 50% market share. Over 70 PDT therapies are under clinical development, with challenges including limited tissue penetration and high system costs.

The cancer metabolism-based therapeutics market is projected to grow from $3.7 billion in 2026 to $26.3 billion by 2035, driven by precision medicine approaches and rising cancer prevalence. The market includes approximately 250 therapeutic programs targeting cancer metabolism vulnerabilities, with North America expected to hold over 45% market share. Key challenges include metabolic pathway complexity and cancer cell plasticity, while strategic collaborations are accelerating development.

Dupilumab (Dupixent) continues strong growth with €10.7 billion in 2023 sales and $4.34 billion in Q2 2025. FDA approval for COPD in September 2024 and expansion to chronic spontaneous urticaria in children unlock new market opportunities. The drug demonstrates clinical superiority over competitors like Xolair, with market projections extending to 2034 across multiple indications and geographic regions.

European stocks are nearly at parity with U.S. stocks, with the Euro Stoxx 50 index up 8.2% year-to-date as of June 30, 2026. The article recommends three European stocks poised to outperform: ArcelorMittal (steel producer), ARM Holdings (semiconductor IP company), and Novartis (biopharma company). While European stock gains have been driven by currency dynamics and valuation re-rating rather than fundamental performance, these three companies offer strong earnings growth prospects for the remainder of 2026.